The new effort combines adaptive platform trial design, AI-enabled site activation, nationwide data infrastructure, and patient data contribution tools to reduce timelines, costs, and patient burden across clinical development.
|Articles|February 6, 2014
NIH, Sponsors, Non-Profits Form Accelerating Medicines Partnership
The NIH, along with 10 biopharma companies and eight non-profit organizations, have formed the Accelerating Medicines Partnership
Advertisement
The NIH, along with 10 biopharma companies and eight non-profit organizations, have formed the Accelerating Medicines Partnership (AMP) in the hopes of accelerating biomarker identification and drug targets in four diseases—Alzheimer's, Type II diabetes, rheumatoid arthritis and lupus—through data sharing. At the foundation of the partnership is the agreement that the data and analyses generated will be made publicly available to the broad biomedical community.
The AMP partners, along with the NIH include FDA, as well as biopharma sponsors AbbVie, Biogen, BMS, GSK, J&J, Lilly, Merck, Pfizer, Sanofi and Takeda. Major disease associations include the Alzheimer’s Association, USAgainstAlzheimer’s, American Diabetes Association, Lupus Foundation of America, and the Rheumatology Research Foundation. All partners have developed research plans and are sharing costs, expertise, and resources in an integrated governance structure. The three- to five-year, milestone-driven pilot projects in these disease areas could set the stage for broadening AMP to other diseases and conditions.
Read the full release
Advertisement
Related to this article
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains how AI is shifting trial risk management from reactive to proactive—enabling sponsors to pressure-test protocols and anticipate pivots before a single patient is enrolled.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
AI agents in clinical operations acquire broader autonomous capability through expanded permissions, tools, memory, and delegated authority, requiring governance focused on whether effective capability has shifted outside approved boundaries rather than whether software has changed.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.
In today's ACT Brief, we examine how data drives honest enrollment assumptions, why RWE infrastructure lags ambition, and the disconnect between FDA rulemaking and enforcement on compounded therapies.
RWE is finding a role earlier in drug development than ever before, but the data quality, integration, and organizational alignment required to make it regulatory-grade are still catching up to the ambition.
In this video interview, Claire Riches, VP of clinical solutions at Citeline, explains why combining analog trial performance data with real-world patient data and site-level recruitment history gives sponsors a far more honest picture of whether their enrollment assumptions are actually achievable.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Control Plane for Agentic Clinical Operations: Governing Autonomous Digital Actors in Regulated Trials
2
Where AI Leads in Trial Design—and Where Humans Still Need To
3
HHS Launches SURPASS Program and Three Complementary Initiatives to Transform Clinical Trial Design and Infrastructure
4
What an AI-Informed Approach Means for How Sponsors Think About Risk
5